Venous Thromboembolism Pipeline Analysis Report 2026

Venous thromboembolism remains a major global cardiovascular concern, encompassing conditions such as deep vein thrombosis and pulmonary embolism that contribute significantly to morbidity and mortality. Pootracool, Piyanut et al., 2024, estimate incidence rates of approximately 104-183 cases per 100,000 individuals annually, with risks increasing sharply with age, hospitalization, cancer, and surgery. The growing disease burden and unmet clinical needs are driving innovation in anticoagulant therapies. According to venous thromboembolism pipeline analysis, safer treatments is expected to drive significant pipeline growth in the coming years.

Report Coverage

The Venous Thromboembolism Pipeline Analysis Report gives comprehensive insights into venous thromboembolism therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for venous thromboembolism. The venous thromboembolism report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The venous thromboembolism pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with venous thromboembolism treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to venous thromboembolism.

Venous Thromboembolism Pipeline Outlook

Venous thromboembolism (VTE) is a condition involving blood clots in veins, primarily deep vein thrombosis (DVT) in deep leg veins or pulmonary embolism (PE) when clots travel to the lungs. It occurs due to slowed blood flow (stasis), vein wall damage, or increased clotting tendency (hypercoagulability), as per Virchow's triad, often triggered by surgery, immobility, cancer, or trauma. This can block blood flow, risking severe complications like heart strain.

Venous thromboembolism treatment strategies typically include anticoagulant therapies such as Heparin, Warfarin, and direct oral anticoagulants to prevent and manage thrombotic events. For instance, in November 2025, the United States Food and Drug Administration expanded approval of THROMBATE III (antithrombin III concentrate) to include pediatric patients with hereditary antithrombin deficiency. The label expansion allows clinicians to use the therapy in both adults and children, improving prevention and treatment strategies for patients at high risk of venous thromboembolism.

Venous Thromboembolism Epidemiology

Venous thromboembolism (VTE), encompassing deep vein thrombosis and pulmonary embolism, remains one of the most common cardiovascular disorders worldwide. Pootracool, Piyanut et al., 2024, estimate a global incidence of approximately 104-183 cases per 100,000 individuals annually, with overall rates commonly reported at 1-2 cases per 1,000 people per year as per Pamela L Lutsey, et al., 2022. According to Peter Marschang et al., 2025, in many Western populations, incidence reaches nearly 150 cases per 100,000 individuals, including around 90 cases of deep vein thrombosis and 67 pulmonary embolism cases per 100,000 people. The risk increases significantly with age, hospitalization, cancer, and major surgery, making VTE a leading cause of preventable hospital-associated morbidity and mortality globally.

Venous Thromboembolism - Pipeline Therapeutic Assessment

This section of the report covers the analysis of venous thromboembolism drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The venous thromboembolism pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Polymers
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Venous Thromboembolism Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III, with 46.%, covers a major share of the total venous thromboembolism clinical trials. Early phase I and phase I each account for nearly 5%, while phase II accounts for 21%, and phase IV 23% of trials.

Venous Thromboembolism Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the venous thromboembolism pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The venous thromboembolism report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for venous thromboembolism. For instance, in March 2025, the United States Food and Drug Administration approved the first generic versions of Xarelto (rivaroxaban) 2.5 mg tablets, an oral Factor Xa inhibitor widely used to prevent and treat thrombotic conditions, including deep vein thrombosis and other clot-related disorders. The approval is expected to improve treatment accessibility and reduce healthcare costs for patients requiring long-term anticoagulant therapy.

Venous Thromboembolism Clinical Trials - Key Players

The report for the venous thromboembolism pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed venous thromboembolism therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in venous thromboembolism clinical trials:

• Regeneron Pharmaceuticals
• Sirius Therapeutics Co., Ltd.
• Anthos Therapeutics, Inc.
• Quercis Pharma AG
• Novartis Pharmaceuticals
• Beijing Suncadia Pharmaceuticals Co., Ltd.
• Suzhou Alphamab Co., Ltd.
• Livzon Pharmaceutical Group Inc.
• Bristol Myers Squibb
• Johnson & Johnson

Venous Thromboembolism - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for venous thromboembolism. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of venous thromboembolism drug candidates.

Drug: REGN9933

REGN9933 is an investigational monoclonal antibody anticoagulant targeting coagulation Factor XI and is being sponsored by Sirius Therapeutics Co., Ltd. in collaboration with Regeneron Pharmaceuticals. The therapy binds to the Factor XI A2 domain, inhibiting activation within the intrinsic coagulation pathway and reducing thrombin generation associated with pathologic clot formation. By selectively targeting Factor XI, the drug aims to prevent thrombosis while minimizing bleeding risk compared with conventional anticoagulants.

Drug: REGN7508

REGN7508 is a human monoclonal antibody targeting coagulation Factor XI and is sponsored by Regeneron Pharmaceuticals, for thromboembolic disorders such as venous thromboembolism. The antibody binds to the catalytic domain of Factor XI, blocking activation within the intrinsic coagulation cascade and reducing the formation of pathological blood clots. This mechanism is designed to provide strong antithrombotic activity while lowering bleeding risks commonly associated with traditional anticoagulants.

Drug: SRSD107

SRSD107 is a small interfering RNA (siRNA) therapeutic targeting Factor XI. The drug being developed by the Sirius Therapeutics Co., Ltd. works by selectively inhibiting the messenger RNA responsible for producing Factor XI, thereby reducing the protein’s expression and suppressing the intrinsic coagulation pathway that drives thrombus formation. This RNA-based mechanism may provide long-lasting anticoagulant effects with potentially lower bleeding risk and extended dosing intervals.

Key Questions Answered in the Venous Thromboembolism Pipeline Insight Report

• Which companies/institutions are leading the venous thromboembolism drug development?
• Which company is leading the venous thromboembolism pipeline development activities?
• What is the current venous thromboembolism commercial assessment?
• What are the opportunities and challenges present in the venous thromboembolism pipeline landscape?
• What is the efficacy and safety profile of venous thromboembolism pipeline drugs?
• Which company is conducting major trials for venous thromboembolism drugs?
• Which companies/institutions are involved in venous thromboembolism collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in venous thromboembolism?

Reasons To Buy This Report

The Venous Thromboembolism Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for venous thromboembolism. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into venous thromboembolism collaborations, regulatory environments, and potential growth opportunities.